Viridian Therapeutics, Inc. (VRDN)
30.06
+0.46
(+1.54%)
USD |
NASDAQ |
Feb 10, 11:16
Viridian Therapeutics EPS Diluted (Quarterly) : -0.423 for Sept. 30, 2025
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Marker Therapeutics, Inc. | -0.1193 |
| ADMA Biologics, Inc. | 0.1489 |
| Avantor, Inc. | -1.044 |
| Immunovant, Inc. | -0.6095 |
| Plus Therapeutics, Inc. | -0.0412 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -34.60M |
| Revenue (Quarterly) | 70.57M |
| Total Expenses (Quarterly) | 105.17M |
| Enterprise Value | 2.547B |
| Gross Profit Margin (Quarterly) | 99.56% |
| Profit Margin (Quarterly) | -49.03% |
| Earnings Yield | -11.76% |
| Normalized Earnings Yield | -11.76 |